![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ATP5J |
Gene summary for ATP5J |
![]() |
Gene information | Species | Human | Gene symbol | ATP5J | Gene ID | 522 |
Gene name | ATP synthase peripheral stalk subunit F6 | |
Gene Alias | ATP5 | |
Cytomap | 21q21.3 | |
Gene Type | protein-coding | GO ID | GO:0002027 | UniProtAcc | P18859 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
522 | ATP5J | P44T-E | Human | Esophagus | ESCC | 3.11e-24 | 1.13e+00 | 0.1096 |
522 | ATP5J | P47T-E | Human | Esophagus | ESCC | 5.32e-24 | 8.14e-01 | 0.1067 |
522 | ATP5J | P48T-E | Human | Esophagus | ESCC | 1.08e-22 | 7.43e-01 | 0.0959 |
522 | ATP5J | P49T-E | Human | Esophagus | ESCC | 1.89e-17 | 2.11e+00 | 0.1768 |
522 | ATP5J | P52T-E | Human | Esophagus | ESCC | 1.59e-68 | 2.00e+00 | 0.1555 |
522 | ATP5J | P54T-E | Human | Esophagus | ESCC | 7.76e-34 | 1.23e+00 | 0.0975 |
522 | ATP5J | P56T-E | Human | Esophagus | ESCC | 2.68e-13 | 1.97e+00 | 0.1613 |
522 | ATP5J | P57T-E | Human | Esophagus | ESCC | 6.81e-30 | 9.24e-01 | 0.0926 |
522 | ATP5J | P61T-E | Human | Esophagus | ESCC | 1.80e-16 | 8.13e-01 | 0.099 |
522 | ATP5J | P62T-E | Human | Esophagus | ESCC | 4.47e-71 | 1.91e+00 | 0.1302 |
522 | ATP5J | P65T-E | Human | Esophagus | ESCC | 3.49e-37 | 1.11e+00 | 0.0978 |
522 | ATP5J | P74T-E | Human | Esophagus | ESCC | 2.13e-64 | 3.00e+00 | 0.1479 |
522 | ATP5J | P75T-E | Human | Esophagus | ESCC | 2.67e-69 | 1.90e+00 | 0.1125 |
522 | ATP5J | P76T-E | Human | Esophagus | ESCC | 3.88e-59 | 1.48e+00 | 0.1207 |
522 | ATP5J | P79T-E | Human | Esophagus | ESCC | 3.88e-46 | 1.21e+00 | 0.1154 |
522 | ATP5J | P80T-E | Human | Esophagus | ESCC | 1.59e-62 | 2.76e+00 | 0.155 |
522 | ATP5J | P82T-E | Human | Esophagus | ESCC | 3.94e-24 | 1.81e+00 | 0.1072 |
522 | ATP5J | P83T-E | Human | Esophagus | ESCC | 5.16e-51 | 2.20e+00 | 0.1738 |
522 | ATP5J | P84T-E | Human | Esophagus | ESCC | 7.52e-09 | 1.17e+00 | 0.0933 |
522 | ATP5J | P89T-E | Human | Esophagus | ESCC | 6.67e-33 | 2.47e+00 | 0.1752 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0501218 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
hsa0502016 | Breast | Precancer | Prion disease | 95/684 | 273/8465 | 1.39e-37 | 1.46e-35 | 1.12e-35 | 95 |
hsa0501616 | Breast | Precancer | Huntington disease | 98/684 | 306/8465 | 2.85e-35 | 2.25e-33 | 1.72e-33 | 98 |
hsa0019016 | Breast | Precancer | Oxidative phosphorylation | 59/684 | 134/8465 | 6.15e-30 | 3.24e-28 | 2.48e-28 | 59 |
hsa0501016 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
hsa0501416 | Breast | Precancer | Amyotrophic lateral sclerosis | 98/684 | 364/8465 | 2.13e-28 | 8.41e-27 | 6.44e-27 | 98 |
hsa0502216 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
hsa0520818 | Breast | Precancer | Chemical carcinogenesis - reactive oxygen species | 68/684 | 223/8465 | 3.61e-23 | 1.14e-21 | 8.73e-22 | 68 |
hsa0471418 | Breast | Precancer | Thermogenesis | 68/684 | 232/8465 | 4.40e-22 | 1.26e-20 | 9.69e-21 | 68 |
hsa0541518 | Breast | Precancer | Diabetic cardiomyopathy | 63/684 | 203/8465 | 5.63e-22 | 1.48e-20 | 1.14e-20 | 63 |
hsa0501219 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
hsa0502017 | Breast | Precancer | Prion disease | 95/684 | 273/8465 | 1.39e-37 | 1.46e-35 | 1.12e-35 | 95 |
hsa0501617 | Breast | Precancer | Huntington disease | 98/684 | 306/8465 | 2.85e-35 | 2.25e-33 | 1.72e-33 | 98 |
hsa0019017 | Breast | Precancer | Oxidative phosphorylation | 59/684 | 134/8465 | 6.15e-30 | 3.24e-28 | 2.48e-28 | 59 |
hsa0501017 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
hsa0501417 | Breast | Precancer | Amyotrophic lateral sclerosis | 98/684 | 364/8465 | 2.13e-28 | 8.41e-27 | 6.44e-27 | 98 |
hsa0502217 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
hsa0520819 | Breast | Precancer | Chemical carcinogenesis - reactive oxygen species | 68/684 | 223/8465 | 3.61e-23 | 1.14e-21 | 8.73e-22 | 68 |
hsa0471419 | Breast | Precancer | Thermogenesis | 68/684 | 232/8465 | 4.40e-22 | 1.26e-20 | 9.69e-21 | 68 |
hsa0541519 | Breast | Precancer | Diabetic cardiomyopathy | 63/684 | 203/8465 | 5.63e-22 | 1.48e-20 | 1.14e-20 | 63 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ATP5J | SNV | Missense_Mutation | novel | c.10N>A | p.Asp4Asn | p.D4N | P18859 | protein_coding | tolerated_low_confidence(0.18) | benign(0.005) | TCGA-E2-A10C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
ATP5J | SNV | Missense_Mutation | novel | c.10N>A | p.Asp4Asn | p.D4N | P18859 | protein_coding | tolerated_low_confidence(0.18) | benign(0.005) | TCGA-LL-A73Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD |
ATP5J | SNV | Missense_Mutation | novel | c.290N>T | p.Thr97Ile | p.T97I | P18859 | protein_coding | deleterious(0.05) | possibly_damaging(0.481) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
ATP5J | SNV | Missense_Mutation | rs140201687 | c.88N>T | p.Arg30Trp | p.R30W | P18859 | protein_coding | tolerated(0.08) | benign(0.019) | TCGA-AX-A06D-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Chemotherapy | carboplatin | PD |
ATP5J | SNV | Missense_Mutation | c.115G>A | p.Ala39Thr | p.A39T | P18859 | protein_coding | tolerated(0.1) | probably_damaging(0.991) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD | |
ATP5J | SNV | Missense_Mutation | c.56N>A | p.Ser19Tyr | p.S19Y | P18859 | protein_coding | deleterious(0) | possibly_damaging(0.747) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
ATP5J | SNV | Missense_Mutation | c.115G>A | p.Ala39Thr | p.A39T | P18859 | protein_coding | tolerated(0.1) | probably_damaging(0.991) | TCGA-BK-A0C9-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
ATP5J | SNV | Missense_Mutation | c.185N>A | p.Arg62Gln | p.R62Q | P18859 | protein_coding | tolerated(0.32) | benign(0.083) | TCGA-BK-A6W3-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
ATP5J | SNV | Missense_Mutation | novel | c.106A>C | p.Thr36Pro | p.T36P | P18859 | protein_coding | deleterious(0.01) | probably_damaging(0.915) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
ATP5J | SNV | Missense_Mutation | novel | c.271N>T | p.Gly91Cys | p.G91C | P18859 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-85-A4QQ-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |